Quick Takeaways
- Fortress Biotech, Inc. filed SCHEDULE 13D/A for Avenue Therapeutics, Inc. Common Stock, $0.0001 Par Value (ATXI).
- Disclosed ownership: 13%.
- Date of event: 02 Jan 2026.
Fortress Biotech, Inc. - 02 Jan 2026 SCHEDULE 13D/A Report for Avenue Therapeutics, Inc. Common Stock, $0.0001 Par Value (ATXI)
- Filing Manager
- Fortress Biotech, Inc.
- Reporting Manager
- Fortress Biotech, Inc.
- Symbol
- ATXI
- Shares outstanding
- 3,283,246 shares
- Disclosed Ownership
- 439,955 shares
- Ownership
- 13%
- Form type
- SCHEDULE 13D/A
- Filing time
- 06 Jan 2026, 16:11:21 UTC
- Date of event
- 02 Jan 2026
- Previous filing
- 02 Apr 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Fortress Biotech, Inc. disclosed 13% ownership in Avenue Therapeutics, Inc. Common Stock, $0.0001 Par Value (ATXI) on 02 Jan 2026."
What Changed
- Previous schedule filing date: 02 Apr 2025.
- Current filing was accepted on 06 Jan 2026, 16:11.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Fortress Biotech, Inc. | 13% | 439,955 | 439,955 | 0 | /s/ Lindsay A. Rosenwald | Lindsay A. Rosenwald, M.D. / Chairman, President and Chief Executive Officer | 0001429260 |